Cost-Effectiveness of Pitavastatin in Dyslipidemia: A Systematic Review

Nam Xuan Vo, Huong Lai Pham, Tan Trong Bui, Tien Thuy Bui · 2026

Read Cost-Effectiveness of Pitavastatin in Dyslipidemia: A Systematic Review by Nam Xuan Vo, Huong Lai Pham, Tan Trong Bui, Tien Thuy Bui (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13361831.txt.

Description

Nam Xuan Vo and co-authors reviewed the cost-effectiveness of a newer statin in a 2026 paper. Faulty blood fats drive heart and vessel disease and a heavy global cost. Statins are the main defense, and pitavastatin is the newest of the class, matching stronger rivals at lowering bad cholesterol. The team searched three databases for economic studies through November 2025.

They compared pitavastatin with atorvastatin and rosuvastatin, the two most used statins. The main measure weighs extra cost against extra health gained, counted in quality-adjusted life years or cholesterol cuts. Study quality was graded with current reporting and bias tools. Health systems must choose which statin to fund, and pooled economic proof helps them spend wisely.

Catalog record

CREATORNam Xuan Vo, Huong Lai Pham, Tan Trong Bui, Tien Thuy Bui
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39091
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13361831

Browse the full library · About the Tower of Babel